Several studies suggested that KRAS/TP53 co-mutation generally present with a significant upregulation of PD-L1 expression and tumoricidal T-cell accumulation, which may help NSCLC patients respond to immunotherapy and get long-term survival [24–27]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.